Lexicon Pharmaceuticals (LXRX) Research & Development: 2009-2011
Historic Research & Development for Lexicon Pharmaceuticals (LXRX) over the last 3 years, with Dec 2011 value amounting to $28.1 million.
- Lexicon Pharmaceuticals' Research & Development rose 53.99% to $28.1 million in Q4 2011 from the same period last year, while for Dec 2011 it was $91.8 million, marking a year-over-year increase of 16.95%. This contributed to the annual value of $91.8 million for FY2011, which is 16.95% up from last year.
- Per Lexicon Pharmaceuticals' latest filing, its Research & Development stood at $28.1 million for Q4 2011, which was up 43.00% from $19.7 million recorded in Q3 2011.
- Lexicon Pharmaceuticals' Research & Development's 5-year high stood at $28.1 million during Q4 2011, with a 5-year trough of $18.3 million in Q4 2010.
- Over the past 3 years, Lexicon Pharmaceuticals' median Research & Development value was $20.1 million (recorded in 2011), while the average stood at $21.0 million.
- Its Research & Development has fluctuated over the past 5 years, first decreased by 7.77% in 2010, then surged by 53.99% in 2011.
- Over the past 3 years, Lexicon Pharmaceuticals' Research & Development (Quarterly) stood at $18.8 million in 2009, then dropped by 3.09% to $18.3 million in 2010, then skyrocketed by 53.99% to $28.1 million in 2011.
- Its last three reported values are $28.1 million in Q4 2011, $19.7 million for Q3 2011, and $20.1 million during Q2 2011.